

Class A and D Extended-Spectrum β -Lactamases in Imipenem Resistant *Pseudomonas aeruginosa* Isolated From Burn Patients in Iran

Sanaz Pakbaten Toupanlou¹; Shahin Najar Peerayeh^{1,*}; Rahim Pirhajati Mahabadi¹

¹Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran

*Corresponding author: Shahin Najar Peerayeh, Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran. Tel: +98-2182884555, Fax: +98-2182884555, E-mail: najarp_s@modares.ac.ir

Received: February 20, 2014; Revised: August 3, 2014; Accepted: September 20, 2014

Background: *Pseudomonas aeruginosa* remains a leading cause of severe wound infection and mortality in burn patients.

Objectives: The current study aimed to determine the prevalence of Ambler class A and D β -lactamases among *P. aeruginosa* isolated from infected burn injuries in Tehran, Iran.

Patients and Methods: Bacteriological samples were taken from burn patients with clinical symptoms of burn infection. Fifty Gram-negative, oxidase-positive, catalase-positive bacilli, grown at 42°C and production of pigment on Mueller-Hinton agar were identified as *P. aeruginosa*. All of the 50 isolates were examined for antibiotic susceptibility via disk diffusion method, and production of Ambler class A and D β -lactamases by phenotypic screening test. The presence of Ambler class A and D β -lactamases was confirmed by polymerase chain reaction technique.

Results: The results showed that the majority of isolates (88%) were multi-drug resistant. Out of these 50 imipenem resistant isolates, 7 (14%), 18 (36%), 18 (36%) and 18 (36%) strains were positive for *bla*_{PER}, *bla*_{OXA-10}, *bla*_{TEM} and *bla*_{SHV} genes alone or in combination, respectively. None of the isolates possessed *bla*_{KPC} or *bla*_{GES} genes.

Conclusions: The current study highlights that the high level of resistance to many antibacterial agents and a gradual increase in the degree of PER, OXA-10, SHV and TEM ESBLs among the majority of imipenem resistant *P. aeruginosa* isolated from patients with burn infection is an enormous threat in burn centers in Iran.

Keywords: Imipenem; *bla*_{PER}, *bla*_{OXA-10}, *bla*_{TEM}, *bla*_{SHV}; *Pseudomonas aeruginosa*

1. Background

The burn wound provides suitable conditions for bacterial growth. Bacterial infection is a serious factor of mortality in burn patients. Incidentally, approximately 75% of the mortality due to burn wounds is associated with infections (1). An opportunistic, nosocomial pathogen of immunocompromised patients, *Pseudomonas aeruginosa*, typically infects the burn wounds. A study revealed that *P. aeruginosa* was isolated from 73.9% of the burn patients in Iran (2, 3). In addition, many studies showed that colonization of these bacteria in burn wounds is a main cause of mortality in burn patients in burn treatment centers in Iran (2).

To treat such infections, carbapenems such as imipenem are identified as the most effective agent against *P. aeruginosa* (4). Although imipenem is known as a potential last treatment option for patients with burn lesions, it was revealed that one of the most concerning characteristics of *P. aeruginosa* species is their high resistance to imipenem in hospitalized burn patients in recent years. were reported 16% - 100% in Tehran hospitals in various studies (5).

Although metallo- β -lactamases (MBLs) are one of the

most important mechanisms resulting in treatment failure in carbapenem therapy of *P. aeruginosa* infections, these isolates also produce β -lactamases of class A and D. Class A extended-spectrum β -lactamases (ESBLs) including TEM, SHV, GES, PER, VEB, CTX-M and IBC families are also found in *P. aeruginosa* strains. extended-spectrum β -lactamases from the class D, OXA-type enzymes are also detected in *P. aeruginosa* (6). Also recently, the number of *P. aeruginosa* isolates producing KPC-type carbapenemases raised significantly (7). Plasmid acquired Ambler class A ESBLs such as GES, PER, SHV and TEM types were normally found in *Enterobacteriaceae*. Class A ESBLs are recently identified in *P. aeruginosa* but they are reported in a limited areas (8). Compared with the enterobacterial species, in which TEM and SHV ESBLs are found most frequently, OXA and PSE types are the most common β -lactamases in *P. aeruginosa* (9).

2. Objectives

To the best of the authors' knowledge, there is not enough information regarding the prevalence of class A and D ESBLs and the type of involved genes in imipenem

resistant *P. aeruginosa* in burn patients in Iran. The current study aimed to investigate the prevalence of GES, PER, SHV, TEM and OXA-10 ESBLs as well as KPC carbapenemases among imipenem resistant *P. aeruginosa* strains isolated from the burn patients hospitalized in several burn treatment centers in Tehran, Iran (2).

3. Patients and Methods

3.1. Bacterial Isolates

Fifty imipenem resistant *P. aeruginosa* species were isolated from hospitalized burn patients from 2009 to 2010 in Tehran, Iran. The isolates were identified as *P. aeruginosa* by conventional biochemical tests such as oxidase and catalase production, growth at 42°C, and production of pigment on Mueller-Hinton agar (Merck, Germany). The isolates were stored at -20°C in brain-heart infusion broth (Merck, Germany) with 15% glycerol for future investigations.

3.2. Susceptibility Tests and Confirmation of ESBLs Production

Antimicrobial susceptibility to various antibiotics was carried out using the disc-diffusion method recommend-

ed by the clinical and laboratory standards institute (CLSI) guidelines (10). Eleven antibacterial discs including cefotaxime (CTX; 30 µg), ceftazidime (CAZ; 30 µg), aztreonam (ATM; 30 µg), gentamicin (GM; 10 µg), ciprofloxacin (CIP; 5 µg), amikacin (AN; 30 µg), tobramycin (TOB; 10 µg), cefepime (CPM; 30 µg), piperacillin (PIP; 100 µg), cefixime (CFM; 5 µg), and ticarcillin (TIC; 75 µg) (MAST, UK) were used. ESBLs phenotypic confirmatory tests were performed by combined disc tests, using CTX and CTX/clavulanic acid (30/10 µg) and CAZ and CAZ/clavulanic acid (30/10 µg) (11). The inhibitory zone diameter ≥ 5 mm was considered positive for ESBLs production.

3.3. Detection of *bla*_{GES}, *bla*_{PER}, *bla*_{SHV}, *bla*_{TEM}, *bla*_{OXA-10} and *bla*_{KPC} Genes by Polymerase Chain Reaction

DNA was extracted by the boiling method (12) and PCR analysis was carried out on all 50 isolates to evaluate the prevalence of the *bla*_{GES}, *bla*_{PER}, *bla*_{SHV}, *bla*_{TEM}, *bla*_{OXA-10} ESBLs and *bla*_{KPC} carbapenemases genes. The DNA amplification program and the specific primers (TAKA-POUZIST, IRAN) used for standard PCR amplification procedures are shown in Table 1 (11, 13-17). To detect DNA fragments PCR products were detected by gel electrophoresis in 1.5% agarose.

Table 1. The DNA Amplification Program and the Specific Primers Used for Standard PCR Procedure

Target	Primer Sequence	Amplicon Size, bp	Initial Denaturation	Second Denaturation	Annealing Stage, for 1 min	First Extension	Last Extension
GES	F (5'-ATGCGCTTCATTCACGCAC-3')	864	94°C for 4 min	35 cycles of denaturation at 94°C for 1 min	60°C	72°C for 1 min	72°C for 10 min
	R (5'-CTATTGTCCGTGCTCAGG-3')						
PER	F (5'-ATG AAT GTC ATT ATA AAA GC-3')	925	94°C for 4 min	35 cycles of denaturation at 94°C for 1 min	55°C	72°C for 1 min	72°C for 10 min
	R (5'-AAT TTG GGC TTA GGG CAG AA-3')						
SHV	F (5'-AAGATCCACTATCGCCAGCAG-3')	231	94°C for 4 min	35 cycles of denaturation at 94°C for 1 min	58°C	72°C for 1 min	72°C for 10 min
	R (5'-ATTCAGTTCGGTTCCAGCGG-3')						
TEM	F (5'-ATGAGT ATTCAACATTTCCG-3')	858	94°C for 4 min	35 cycles of denaturation at 94°C for 1 min	55°C	72°C for 1 min	72°C for 10 min
	R (5'-CCAATGCTTAATCAGTGAGG-3')						
OXA-10	F (5'-TCAACAAATCGCCAGAGAAG-3')	276	94°C for 4 min		58°C	72°C for 1 min	72°C for 10 min
	R (5'-TCCACACCAGAAAACCAG-3')						
KPC	F (5'-ATGTCAGTGTATCGCCGTCT-3')	893	94°C for 4 min	35 cycles of denaturation at 94°C for 1 min	52°C	72°C for 1 min	72°C for 10 min
	R (5'-TTTTAGAGCCCTTACTGCCC-3')						

4. Results

The results of antibiogram testing showed that all isolates (100%) were resistant to CTX, CPM, PIP, CFM and TIC. Meanwhile, the findings revealed that 49 (98%) isolates were resistant to CAZ, CIP and 48 (96%) isolates were resistant to ATM, AN, GM and TOB. Most of the isolates were resistant to various classes of antibacterial agents (Table 2). Among the 50 isolates, 44 (88%) were multi-drug resistant and phenotypic tests indicated that 27 (54%) strains were presumed ESBLs producers. Among the 27 strains, 23 (85.18%) were determined with zone diameters of 5 - 14 mm in combination with CAZ/clavulanic acid and 17 (62.96%) were determined with zone diameters of 5 - 12 mm in combination with CTX/clavulanic acid.

PCR analysis was carried out for all 50 isolates using primers specific to *bla*_{PER}, *bla*_{GES}, *bla*_{OXA-10}, *bla*_{TEM}, *bla*_{SHV} and


*bla*_{KPC}. Four of six genes were detected alone or in various combinations; 7 (14%), 18 (36%), 18 (36%), 18 (36%) strains of a total of 50 isolates were amplified as *bla*_{PER}, *bla*_{OXA-10}, *bla*_{TEM} and *bla*_{SHV}, respectively (Figure 1). Whilst among the 27 isolates indicated as presumed ESBLs producers phenotypically, 3 (11.11%), 12 (42.85%), 14 (50%) and 14 (50%) strains were detected as *bla*_{PER}, *bla*_{OXA-10}, *bla*_{TEM} and *bla*_{SHV} genes, respectively. In addition, among isolates, 10 (20%) carried *bla*_{TEM}, *bla*_{OXA-10} and *bla*_{SHV} genes, simultaneously. Also 98% of SHV, TEM and OXA-10 producing strains were resistant to all of the antibiotics used in this research. No *bla*_{KPC} and *bla*_{GES} genes were detected in the study. Table 3 shows that approximately all of the isolates harboring multiple antimicrobial resistance genes were 100% resistant to different classes of antibiotics except CIP.

Table 2. Relationship Between Antibacterial Pattern and Imipenem Resistant Isolates Carrying ESBLs Genes Alone ^a

Antibiotics	Antibiotic Resistant Isolates Carrying ESBLs Genes Alone			
	PER: 14%	SHV: 36%	TEM: 36%	OXA-10: 36%
CTX	100	100	100	100
CAZ	100	100	100	100
ATM	100	100	100	100
GM	98	100	100	100
CIP	100	98	98	100
AN	98	100	100	100
TOB	98	100	100	100
CPM	100	100	100	100
PIP	100	100	100	100
CFM	100	100	100	100
TIC	100	100	100	100

^a Abbreviations: AN, amikacin; ATM, aztreonam; CAZ, ceftazidime; CFM, cefixime; CIP, ciprofloxacin; CPM, cefepime; CTX, cefotaxime; GM, gentamicin; PIP, piperacillin; R, resistant; TIC, ticarcillin; TOB, tobramycin.

Figure 1. Electrophoresis of PCR Products for Amplifying *bla*_{GES}, *bla*_{PER}, *bla*_{SHV}, *bla*_{TEM}, *bla*_{OXA-10} and *bla*_{KPC} Genes



No 1, DNA marker (100 kb). No 2, *bla*_{SHV} (231 bp), No 3, *bla*_{TEM} (858 bp), No 4, *bla*_{OXA-10} (276), No 5, positive control for *bla*_{GES} (864 bp), No 6, positive control for *bla*_{KPC} (893 bp), No 7, *bla*_{PER} (925 bp).

Table 3. Relationship Between Antibacterial Pattern and Imipenem Resistant Isolates Carrying ESBLs Genes in Various Combinations ^a

Antibiotics	Resistant Isolates Carrying ESBL Genes	
	TEM + SHV	PER + OXA
CTX	100	100
CAZ	100	100
ATM	100	100
GM	100	100
CIP	6.25	100
AN	100	100
TOB	100	100
CPM	100	100
PIP	100	100
CFM	100	100
TIC	100	100

^a Abbreviations: AN, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; CFM, cefixime; CPM, cefepime; CTX, cefotaxime; GM, gentamicin; TOB, tobramycin; PIP, piperacillin; TIC, ticarcillin.

5. Discussion

The application of antibiotics is one of the most important scientific attainments of the 20th century. However, prevalent antibiotic use increases antibiotic-resistant pathogens, including multidrug resistant isolates (18). Antibiotic resistance of pathogenic bacteria is a major global danger and Realization of the resistance mechanisms is critical to development of novel therapeutic options (18). *Pseudomonas aeruginosa* is the predominant bacterial pathogen in patients with burn injuries. The resistance of this microorganism to antibiotics is a worrisome problem in hospitalized patients with burn injuries. Extended spectrum β -lactamases, carbapenemases, metallo β -lactamases and AmpC β -lactamases producing organisms are the main problems to treat the infected burn patients in burn centers (1). One of the most important ways to select an effective method to reduce such infections is specifying the relationship between genotype and drug susceptibility (1). Multidrug-resistant *P. aeruginosa* isolates re a worrying matter from burn patients in Iran (19). Several classes of ESBLs such as OXA, PER, TEM, SHV and GES are newly detected in *P. aeruginosa*. Also recently, the number of *P. aeruginosa* isolates producing KPC-type carbapenemases has significantly raised (7).

The findings of the present study explained that high levels of resistance to many antimicrobial antibiotics existed among *P. aeruginosa* isolated from the infected wounds of burn patients and the majority of isolates (88%) were multi-drug resistant. All isolates were totally resistant to CTX, CPM, PIP, CFM and TIC; whereas the minimum resistance rate (96%) was demonstrated for ATM, GM, TOB and AN. Results of the previous studies approved resistance to a large number of antibiotics usually used to treat burn injuries caused by *P. aeruginosa* in the Iranian hospitals (19). For instance, Shahcheraghi et al. reported that nosocomial *P. aeruginosa* isolates were resistant to cefotaxime (56%) and ceftazidime (25%) (20). In another study, the rates of resistance were as follows: ceftazidime (74.8%) and cefotaxime (50.4%) (19). Moreover, among 27 isolates, phenotypically positive for ESBLs production, 0 (0%), 12 (42.85%), 14 (50%) and 14 (50%) strains were detected as *bla*_{PER}, *bla*_{OXA-10}, *bla*_{TEM} and *bla*_{SHV} genes, respectively. Shahcheraghi et al. reported that the frequency of *bla*_{PER}, *bla*_{TEM}, *bla*_{SHV} and *bla*_{GES} were 17%, 9%, 22% and 0%, respectively (20).

To find more information about the prevalence and type of the relevant genes involved in the multi-drug resistance of nosocomial *P. aeruginosa* isolates, the PCR experiments were performed for all 50 isolates. Of the 50 isolates, 7 (14%), 18 (36%), 18 (36%) and 18 (36%) strains were positive for *bla*_{PER}, *bla*_{OXA-10}, *bla*_{TEM} and *bla*_{SHV} alone or in various combinations, respectively. In addition, earlier reports from Iran also showed that the prevalence of *bla*_{PER-1} and *bla*_{OXA-10} were 49.25% and 74.62%, respectively (2). The observations suggest that the prevalence of *bla*_{OXA-10}, *bla*_{TEM} and *bla*_{SHV} among all of the 50 isolates

were relatively high in the present work. Except in Turkey, in which PER (86%) and OXA-10 (55%) as well as Saudi Arabia in which OXA-10 (56%) and GES (20%) producing *P. aeruginosa* strains were reported (21, 22), no current data existed on the real prevalence of these genes in the countries neighboring Iran. It is possible that the distribution of PER and OXA-10 probably associated with the immigration and traveling between Iran and Turkey.

A study conducted in Taiwan showed that TEM, SHV-18 and OXA-10 genes exist in 100%, 91.3% and 21.7% of the total *P. aeruginosa* strains, respectively (23). Based on the results of PCR assay, there were no *bla*_{GES} and *bla*_{KPC} genes in the 50 tested isolates of *P. aeruginosa* in the current study. There are several case reports on the isolation of KPC-producing *P. aeruginosa* and *Klebsiella* species in burned patients in Iran (24, 25). There seems to be a gradual increase in KPC-producing *P. aeruginosa* in the burn centers of Iran. From the clinical point of view, occurrence of KPC-producer Gram-negative bacteria among the burned patients causes a much higher degree of resistance to many antibacterial agents including β -lactams, quinolones and aminoglycosides (26). These findings increase the concern about the future of antibiotic therapy for KPC-producing *P. aeruginosa* strains.

In conclusion, the current study described that the high rates of resistance to different antibacterial agents and a gradual increase in the degree of PER, OXA-10, SHV and TEM ESBLs among the majority of imipenem resistant *P. aeruginosa* isolated from the burn patients with infected wounds is an enormous threat in burn centers of Iran. Therefore, molecular epidemiologic studies play a significant role in the evaluation of transmission ways of the pathogen for infection control.

Acknowledgements

The authors are very grateful to Professor Nordmann for providing the control strain harboring *bla*_{GES} and Dr. Shahcheraghi for providing the control strain harboring *bla*_{KPC} genes.

Authors' Contributions

All the experimental works and data analysis are done by Sanaz Pakbaten Toupanlou and Rahim Pirhajati Mahabadi; Dr. Shahin Najjar Peerayeh supervised the research.

Funding/Support

This work was financially supported by grants from faculty of medical sciences, Tarbiat Modares university, Tehran, Iran.

References

1. Bandekar N, Vinodkumar CS, Basavarajappa KG, Prabhakar PJ, Nagaraj P. Beta lactamases mediated resistance amongst gram negative bacilli in Burn Infection. *Biol Med Res*. 2003;2(3):766-70.
2. Mirsalehian A, Feizabadi M, Nakhjavani FA, Jabalameli F, Goli

- H, Kalantari N. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing *Pseudomonas aeruginosa* strains isolated from burn patients. *Burns*. 2010;**36**(1):70-4.
3. Rastegar Lari A, Bahrami Honar H, Alaghebandan R. Pseudomonas infections in Tohid Burn Center, Iran. *Burns*. 1998;**24**(7):637-41.
 4. Laupland KB, Parkins MD, Church DL, Gregson DB, Louie TJ, Conly JM, et al. Population-based epidemiological study of infections caused by carbapenem-resistant *Pseudomonas aeruginosa* in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains. *J Infect Dis*. 2005;**192**(9):1606-12.
 5. Moazami-Goudarzi S, Eftekhari F. Assessment of carbapenem susceptibility and multidrug-resistance in *Pseudomonas aeruginosa* burn isolates in Tehran. *Jundishapur J Microbiol*. 2013;**6**(2):162-5.
 6. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev*. 2009;**22**(4):582-610.
 7. Wang XD, Cai JC, Zhou HW, Zhang R, Chen GX. Reduced susceptibility to carbapenems in *Klebsiella pneumoniae* clinical isolates associated with plasmid-mediated beta-lactamase production and OmpK36 porin deficiency. *J Med Microbiol*. 2009;**58**(Pt 9):1196-202.
 8. Shakibaei MR, Shahcheraghi F, Hashemi A, Adeli S. Detection of TEM, SHV and PER type extended-spectrum β -lactamase genes among clinical strains of *Pseudomonas aeruginosa* isolated from burn patients at Shafa-hospital, Kerman, Iran. *Iran J Basic Med Sci*. 2008;**11**(104-11)
 9. Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum beta-lactamases in *Pseudomonas aeruginosa*: novel developments and clinical impact. *Antimicrob Agents Chemother*. 2003;**47**(8):2385-92.
 10. Clinical and Laboratory Standards Institute. *Performance standards for Antimicrobial susceptibility Testing: Document M-100-S20*. Wayne, PA, USA: CLSI; 2010.
 11. Jiang X, Zhang Z, Li M, Zhou D, Ruan F, Lu Y. Detection of extended-spectrum beta-lactamases in clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2006;**50**(9):2990-5.
 12. Nguyen TV, Le Van P, Le Huy C, Gia KN, Weintraub A. Detection and characterization of diarrheagenic *Escherichia coli* from young children in Hanoi, Vietnam. *J Clin Microbiol*. 2005;**43**(2):755-60.
 13. Poirel L, Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum beta-lactamase, and the class 1 integron In52 from *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2000;**44**(3):622-32.
 14. Kim J, Lim YM, Rheem I, Lee Y, Lee JC, Seol SY, et al. CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae* collected from 3 university hospitals within Korea. *FEMS Microbiol Lett*. 2005;**245**(1):93-8.
 15. Leila N, Fereshteh S, Nikbin VS, Shoeib N. PER, CTX-M, TEM and SHV Beta-lactamases in clinical isolates of *Klebsiella pneumoniae* isolated from Tehran, Iran. *Iran J Basic Med Sci*. 2010;**13**(3):111-8.
 16. Bhattacharjee A, Sen MR, Anupurba S, Prakash P, Nath G. Detection of OXA-2 group extended-spectrum-beta-lactamase-producing clinical isolates of *Escherichia coli* from India. *J Antimicrob Chemother*. 2007;**60**(3):703-4.
 17. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol Rev*. 2007;**20**(3):440-58.
 18. Kumar A, Schweizer HP. Bacterial resistance to antibiotics: active efflux and reduced uptake. *Adv Drug Deliv Rev*. 2005;**57**(10):1486-513.
 19. Salimi H, Yakhchali B, Owlia P, Lari AR. Molecular Epidemiology and Drug Susceptibility of *Pseudomonas aeruginosa* Strains Isolated From Burn Patients. *Lab Med*. 2010;**41**(9):540-4.
 20. Shahcheraghi F, Nikbin VS, Feizabadi MM. Prevalence of ESBLs genes among multidrug-resistant isolates of *Pseudomonas aeruginosa* isolated from patients in Tehran. *Microb Drug Resist*. 2009;**15**(1):37-9.
 21. Tawfik AF, Shibl AM, Aljohi MA, Altammami MA, Al-Agamy MH. Distribution of Ambler class A, B and D beta-lactamases among *Pseudomonas aeruginosa* isolates. *Burns*. 2012;**38**(6):855-60.
 22. Aktas Z, Poirel L, Salcioglu M, Ozcan PE, Midilli K, Bal C, et al. PER-1- and OXA-10-like beta-lactamases in ceftazidime-resistant *Pseudomonas aeruginosa* isolates from intensive care unit patients in Istanbul, Turkey. *Clin Microbiol Infect*. 2005;**11**(3):193-8.
 23. Du SJ, Kuo HC, Cheng CH, Fei ACY, Wei HW, Chang SK. Molecular mechanisms of ceftazidime resistance in *Pseudomonas aeruginosa* isolates from canine and human infections. *Vet Med*. 2010;**55**(4):172-18.
 24. Azimi L, Rastegar Lari A, Alaghebandan R, Alinejad F, Mohammadpoor M, Rahbar M. KPC-producer gram negative bacteria among burned infants in Motahari Hospital, Tehran: first report from Iran. *Ann Burns Fire Disasters*. 2012;**25**(2):74-7.
 25. Rastegar Lari A, Azimi L, Rahbar M, Fallah F, Alaghebandan R. Phenotypic detection of *Klebsiella pneumoniae* carbapenemase among burns patients: first report from Iran. *Burns*. 2013;**39**(1):174-6.
 26. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. *Clin Infect Dis*. 2011;**53**(1):60-7.